surfactant

[키워드] 1:1 6 hour accompany acute respiratory distress syndrome addition adjusted Administered age anticipated approach ARDS Assessing auxiliary Bacterial blinded Care Clinical outcome control group COVID-10 COVID-19 COVID-19 patient discharge disease dissemination dose doses ECMO element etiology Existence extracorporeal membrane oxygenation Face mask Healthcare provider hospital hospital discharge rate Randomised controlled trial Hospital length of stay ICU information intervention group intubation investigator Iran less lung involvement mechanical ventilation moderate Mortality much lower number objective outcome P/F ratio parallel group participant Patient patient mortality patients with COVID-19 Pneumonia protocol pulmonary disease pulmonary involvement random randomisation randomised randomised controlled trial receive Registration researchers Sample size SARS-CoV-2 second dose sequence severe ARDS status Study protocol surfactant Tehran the patient time Trial ventilator Version Volume website written consent
[DOI] 10.1186/s13063-020-04815-z PMC 바로가기 [Article Type] Letter